Geneoscopy
Geneoscopy is a St. Louis-based molecular diagnostics company that developed ColoSense, the first FDA-approved RNA-based stool test for non-invasive colorectal cancer screening in average-risk adults aged 45 and older, distributed nationwide through Labcorp and reimbursed by Medicare and commercial payors.
- Company typePrivate
- Founded2015
- HeadquartersSaint Louis, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
Geneoscopy firmographics
Firmographics- Name
- Geneoscopy
- Legal name
- Geneoscopy, Inc.
- Website
- https://geneoscopy.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Geneoscopy is a St. Louis-based molecular diagnostics company that developed ColoSense, the first FDA-approved RNA-based stool test for non-invasive colorectal cancer screening in average-risk adults aged 45 and older, distributed nationwide through Labcorp and reimbursed by Medicare and commercial payors.
- Ownership category
- akta.pro rank
Geneoscopy industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industries
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Geneoscopy is headquartered
LocationHeadquarters
- HQ city
- Saint Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Geneoscopy business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Diagnostic Test Sales - ColoSense: Geneoscopy generates revenue through the sale of its FDA-approved ColoSense colorectal cancer screening test. The test is performed at Geneoscopy's CLIA/CAP accredited laboratory in St. Louis. Revenue is derived from reimbursement from Medicare, Medicare Advantage, and commercial payors for eligible screening tests ordered by healthcare providers.
- Laboratory Services: The company operates its own FDA-approved clinical laboratory to process ColoSense tests. Revenue is generated per test performed, with coverage established through CMS (Medicare) and commercial insurance agreements.
- Biopharma Research Partnerships: Geneoscopy provides biomarker analysis services to biopharma companies conducting clinical trials. The company's RNA extraction platform can be used as clinical trial tools to help reduce costs and accelerate studies for GI therapies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Medicare-covered screening test for eligible beneficiaries |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Geneoscopy product offering
Product offeringCore offering
Geneoscopy develops, manufactures, and performs the FDA-approved ColoSense test, a non-invasive multi-target stool RNA (mt-sRNA) screening assay for colorectal cancer and advanced adenomas in average-risk adults aged 45 and older. The company processes samples at its own CLIA/CAP-accredited clinical laboratory in St. Louis, MO, and is extending its proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform into inflammatory bowel disease diagnostics and biopharma research partnerships.
Product overview
Geneoscopy operates a platform-based business model centered on its proprietary stool-derived eukaryotic RNA (seRNA) biomarker technology. The company's flagship product is ColoSense, the first FDA-approved RNA-based stool test for colorectal cancer screening in average-risk adults aged 45 and older. The seRNA platform extracts and analyzes human RNA from stool samples to detect biomarkers associated with colorectal neoplasia and inflammatory bowel disease. Geneoscopy is expanding its diagnostic pipeline to address inflammatory bowel disease through partnerships with biopharmaceutical companies, while continuing to advance its core colorectal cancer screening franchise.
Differentiator
Problem solved
Functional benefit
Brands
- ColoSense: FDA-approved noninvasive multi-target stool RNA (mt-sRNA) colorectal cancer screening test for adults aged 45 and older at average risk for colorectal cancer.
Products and services
- ColoSense FDA-approved noninvasive multi-target stool RNA (mt-sRNA) screening test for colorectal cancer (CRC) and advanced adenomas in average-risk adults aged 45 and older. The first and only FDA-approved stool RNA test for CRC screening, using proprietary RNA biomarkers to detect colorectal neoplasia-associated markers and occult hemoglobin in stool samples. Indicated for adults aged 45-85 at average risk for CRC; covered by Medicare and Medicare Advantage.
- Biopharma Biomarker Research Services Contract biomarker analysis services provided to biopharmaceutical companies conducting clinical trials in gastrointestinal diseases. Geneoscopy's RNA extraction and analysis platform is used as a clinical trial tool to identify immunological markers predicting patient response to therapy, monitor mucosal healing, and reduce required colonoscopies in IBD and other GI therapy trials.
Quantifiable outcome
- 93% sensitivity for colorectal cancer detection
- +8 more outcomes
Companies that use Geneoscopy
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Geneoscopy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability2 records
Feature6 records
Geneoscopy partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and major.
- Bio-Rad LaboratoriescoreBio-Rad led Geneoscopy's $105M Series C funding round and provides its QXDx ddPCR technology for use with Geneoscopy's ColoSense test. The partnership combines Geneoscopy's RNA biomarker platform with Bio-Rad's droplet digital PCR instruments, advancing ddPCR as a foundational technology for oncology diagnostics applications.
- Adiso TherapeuticsmajorStrategic collaboration to use Geneoscopy's RNA biomarker technology as a precision immunology measure in Adiso's ADS051 Phase 2 IBD trial. Geneoscopy will assess stool-based transcriptome changes to identify immunological markers predicting patient response to therapy, advancing non-invasive diagnostics for IBD treatment monitoring.
- LabcorpcoreMulti-year commercial collaboration for nationwide distribution of ColoSense. Labcorp offers Geneoscopy's FDA-approved RNA-based colorectal cancer screening test through its comprehensive laboratory services, enabling healthcare providers to order the test as part of routine screening programs. Test processing occurs at Geneoscopy's facility with samples collected at Labcorp locations.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Geneoscopy competitors and assessment
Company assessmentDirect peers
- Exact Sciences: Exact Sciences markets Cologuard, the dominant noninvasive stool-DNA colorectal cancer screening test. Cologuard is Geneoscopy's most direct competitor in the average-risk CRC screening market and the primary incumbent Geneoscopy must displace to gain share.
- Guardant Health: Guardant Health's Shield is a blood-based colorectal cancer screening test. As an emerging alternative modality in the same screening market, Shield directly competes for the same at-home screening patient and shares the convenience narrative that drives patient compliance.
- Freenome: Freenome is developing a blood-based multi-omic CRC screening test and represents a next-generation competitor in the noninvasive screening space. Its blood-based approach targets the same patient convenience gap that Geneoscopy's stool RNA test addresses.
Broad incumbents
- Labcorp: Labcorp is one of the two largest clinical laboratory services companies in the US and serves as Geneoscopy's nationwide distribution partner for ColoSense. While a partner, Labcorp's broad diagnostic portfolio and incumbent position in CRC screening (including potential competing tests) make it both an enabler and a strategic variable.
- Quest Diagnostics: Quest Diagnostics is a national clinical laboratory giant offering a broad menu of diagnostic services including CRC screening options. As a broad incumbent in the same channel that drives physician test ordering, Quest competes for the same screening volume that ColoSense targets.
- Hologic: Hologic is a major women's health and diagnostics company that has expanded into oncology diagnostics via the Biotheranostics acquisition. It operates in adjacent cancer diagnostics and employs commercial leadership profiles similar to Geneoscopy's go-to-market motion.
- Becton Dickinson: Becton Dickinson is a major diagnostics and life sciences company with a broad portfolio including molecular diagnostics and laboratory instrumentation. It competes in the broader CRC and clinical diagnostics space and represents a potential strategic acquirer of platform diagnostics assets.
Emerging players
- Mainz Biomed: Mainz Biomed is developing ColoAlert, a stool-based CRC screening test with molecular biomarkers. As a smaller European-rooted competitor pursuing the same noninvasive CRC screening opportunity, Mainz Biomed represents an emerging competitive threat particularly in international expansion scenarios.
- VolitionRx: VolitionRx is developing NuQ blood-based cancer diagnostic tests, including applications in colorectal cancer. Its blood-based approach intersects with the broader noninvasive CRC screening market that Geneoscopy targets with its stool RNA platform.
Others
- Bio-Rad Laboratories: Bio-Rad is the manufacturer of the QXDx ddPCR system used in the ColoSense workflow and led Geneoscopy's $105M Series C round. While not a direct competitor, Bio-Rad is an enabling technology partner and investor whose strategic interests are tightly linked to Geneoscopy's commercial success.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Geneoscopy social profiles
Digital presenceGeneoscopy compliance and trust
Trust signalCompliance4 records
Geneoscopy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Geneoscopy leadership team
Management profileNumber of profiles
Profiles10 records
Geneoscopy funding detail
Funding detailFunding overview
Funding rounds5 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Geneoscopy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Geneoscopy
What does Geneoscopy do?
Geneoscopy develops, manufactures, and performs the FDA-approved ColoSense test, a non-invasive multi-target stool RNA (mt-sRNA) screening assay for colorectal cancer and advanced adenomas in average-risk adults aged 45 and older. The company processes samples at its own CLIA/CAP-accredited clinical laboratory in St. Louis, MO, and is extending its proprietary stool-derived eukaryotic RNA (seRNA) biomarker platform into inflammatory bowel disease diagnostics and biopharma research partnerships.
Is Geneoscopy a public or private company?
Geneoscopy is a private company. It is classified as venture growth investor backed and is currently operating.
When was Geneoscopy founded?
Geneoscopy was founded in 2015. It employs 51 to 100 people.
Where is Geneoscopy based?
Geneoscopy is headquartered in Saint Louis, United States, in the North America region.
How does Geneoscopy make money?
Three revenue lines are on record. Diagnostic Test Sales - ColoSense is the primary driver. The others are laboratory Services and biopharma Research Partnerships.
Who are Geneoscopy's main competitors?
Direct peers on record are Exact Sciences, Guardant Health and Freenome. Broad incumbents are Labcorp, Quest Diagnostics, Hologic and Becton Dickinson. Emerging players are Mainz Biomed and VolitionRx. Bio-Rad Laboratories is listed as an others.
Does Geneoscopy have an API?
No public API is recorded for Geneoscopy.
What industry is Geneoscopy in?
Geneoscopy's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics). Its NAICS code is 621511 and its SIC code is 8071.